Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: placebo, Exenatide LAR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 7
States / cities: Walnut Creek, California • Honolulu, Hawaii • St Louis, Missouri + 4 more

Conditions: Peripheral T-cell Lymphoma NOS, Mycosis Fungoides, Sezary Syndrome, Anaplastic Large Cell Lymphoma
Interventions: rhIL-15, Avelumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer
Interventions: LMB-9 immunotoxin; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes, Type 2 Diabetes (T2D)
Interventions: CareSmarts Mobile Health Diabetes Program, Standard of Care Reminders and Self Assessments; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Carrier State, Pancreatic Disease, Kidney Diseases
Interventions: Not listed
Lead sponsor: Philip Polgreen; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,250 participants
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Osteoporosis
Interventions: Treadmill Exercise, Magnitude of Ca loss during Exercise at 26 degrees Celcius; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 60 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Osteoarthritis
Interventions: patient and provider intervention; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Post-COVID-19 Syndrome, Postural Tachycardia Syndrome, Dysautonomia
Interventions: Non-invasive vagus nerve stimulation, Sham Intervention; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Smoking, Smoking Behaviors, Nicotine Dependence
Interventions: E-cigarette with 2.4% Nicotine with Menthol and Tobacco Flavors, E-cigarette with 2.4% Nicotine with Tobacco Flavor Only, E-cigarette with 5% Nicotine with Menthol and Tobacco Flavors, E-cigarette with 5% Nicotine with Tobacco Flavor Only, Tobacco Pouches with 3mg Nicotine with Menthol and Tobacco Flavors, Tobacco Pouches with 3mg Nicotine with Tobacco Flavor Only, Tobacco Pouches with 6mg Nicotine with Menthol and Tobacco Flavors, Tobacco Pouches with 6mg Nicotine with Tobacco Flavor Only; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 21 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Depression, Loneliness, Social Isolation, Depressive Disorder, Mood Disorders, Mental Disorder
Interventions: Empower@Home:Connected; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 60 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions: Rituximab, Tafasitamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Survey Administration; Biological · Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alcoholism
Interventions: Placebo Oral Tablet, Naltrexone; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 64 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Head and Neck Cancer
Interventions: Questionnaires, Acupuncture, Electroencephalogram (EEG); Behavioral · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kidney Diseases
Interventions: YSPSL, placebo; Drug
Lead sponsor: Y's Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more

Conditions: Congestive Heart Failure
Interventions: Placebo, Cinaciguat (BAY58-2667); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: San Diego, California • Washington D.C., District of Columbia • Boston, Massachusetts + 3 more

Conditions: Healthy, Nervous System Disease
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autism Spectrum Disorder
Interventions: Not listed
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 6 Years and older
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: Alcohol Use Disorder (AUD), Nicotine Use Disorder
Interventions: Contingency Management, Non-contingent control; Behavioral
Lead sponsor: Washington State University; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Spasticity
Interventions: Corabotase, Placebo, Dysport; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more

Conditions: Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Anxiety, Depression, Unspecified Adult Solid Tumor, Protocol Specific, Cancer, Cognitive Behavioral Therapy
Interventions: Brief Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Eosinophilic Esophagitis
Interventions: SECM Capsule; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Thyroid Carcinoma
Interventions: LBH589; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: Green Bay, Wisconsin • Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Non-Melanoma Skin Cancer (NMSC)
Interventions: OFDI; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

NYULMC CareSmarts Pilot

The Effects of the CF Carrier State on the Kidneys and Pancreas

PTH And Calcium Responses to Exercise (PACE) in Older Adults

Pilot Testing a Patient and Provider Intervention for Managing Osteoarthritis in Hispanic Adults.

VNS for Long-COVID-19

Effects of E-cigs vs Pouches on Cigarette Smoking and Addiction

Empower@Home:Connected - Feasibility and Preliminary Effect Study

Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

Understanding Treatment Response With Naltrexone Among White Alcoholics

Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia

YSPSL for Prevention of Delayed Graft Function Part B

Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667

Functional and Metabolic Imaging Using Magnetic Resonance Imaging and Spectroscopy

Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort

Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

Brief CBT for Anxiety and Advanced Cancer

Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus

Trial of LBH589 in Metastatic Thyroid Cancer

Optical Frequency Domain Imaging for Non-melanoma Skin Cancers